Wegovy update

Wegovy 7.2mg in the UK

Wegovy’s familiar maintenance dose is 2.4mg weekly, but the MHRA has approved use up to a maximum of 7.2mg weekly for adult patients with obesity where clinically appropriate and prescribed. The 7.2mg dose should only be used exactly as directed by a prescriber.

This page explains UK regulatory updates and evidence context. It does not tell you whether a higher dose is right for you — only your prescriber can decide after reviewing your history, response and monitoring plan.

When to get help

  • Seek urgent medical help for severe or persistent abdominal pain, especially if it spreads to your back or comes with vomiting.
  • Speak to a clinician urgently if vomiting or diarrhoea is persistent or you cannot keep fluids down.
  • Call NHS 111 or seek emergency care if you have signs of a serious allergic reaction, sudden vision changes on semaglutide, or any symptom your prescriber told you to treat as urgent.

Always follow your prescriber, pharmacist or nurse. SlimBee does not provide personal medical advice.

MHRA approvals

In January 2026 the MHRA announced approval of Wegovy up to 7.2mg weekly for adult patients with obesity. See MHRA approval of Wegovy up to 7.2mg.

In April 2026 the MHRA announced approval of a single-dose 7.2mg Wegovy pen for adult patients with obesity. See MHRA approval of the single-dose 7.2mg Wegovy pen.

STEP UP trial (careful framing)

The STEP UP phase 3b trial compared once-weekly semaglutide 7.2mg with semaglutide 2.4mg and placebo over 72 weeks in adults with obesity. Results were published in STEP UP trial (The Lancet Diabetes & Endocrinology, 2025) in 2025.

Trial averages are not guarantees for any individual. Outcomes depend on adherence, lifestyle support, starting weight, dose reached and medical history.

7.2mg is not for everyone

Wegovy dose schedule Full Wegovy guide

Medical disclaimer: Information only — not medical advice. Report suspected side effects via the MHRA Yellow Card scheme.